Longevity and Mortality Investor publishes October 2026 issue

Longevity and Mortality Investor has released its October 2026 edition, with new analysis on life settlements, longevity risk and reverse mortgages. The issue highlights market expansion in life settlements, a California insurable-interest ruling, and further declines in U.S. HECM endorsements.

Why it matters: - The October 2026 issue pulls together developments that affect retirement funding, insurer assumptions, investor strategy and mortgage-market reform. - The edition focuses on markets where demographic change and capital-market demand are reshaping long-term financial products.

What happened: - Longevity and Mortality Investor published its October 2026 issue on Oct. 15, 2026. - The issue includes analysis, commentary and interviews covering life settlements, longevity risk and reverse mortgages. - The full issue is available at the publication website.

The details: - A new Conning study suggests the life settlement market is positioned for long-term expansion. - The study points to investor demand for low-correlation assets, ageing populations, rising retirement and long-term care funding needs, and greater consumer awareness. - In the issue’s life settlement coverage, Greg Winterton speaks with Scott Hawkins, head of insurance research at Conning, about the need for greater awareness, standardisation and investment capital. - The issue also looks at structuring life settlement vehicles in Ireland. - Greg Winterton speaks with David Naughton, partner at Byrne Wallace Shields, about the relative advantages of Qualifying Investor Alternative Investment Funds and Section 110 special purpose companies. - The article argues that Ireland remains an attractive domicile for life settlement investment strategies. - The litigation section covers a ruling by Judge Thomas J. Lo of the Superior Court of California, Orange County. - The judge denied Pacific Life Insurance Company’s motion for summary judgment and U.S. Bank National Association’s cross-motion for summary judgment in an insurable-interest lawsuit involving a $20 million life insurance policy. - The guest article asks whether dementia could become the next major longevity event. - Richard Marshall, senior director, and Scott Hamilton, director, in WTW’s UK Life Insurance practice examine how dementia prevention, diagnosis and treatment could affect mortality improvement trends and longevity assumptions. - The Q&A features Beat Hess, managing partner of AA-Partners. - Hess says Distributed to Paid-In is a more meaningful measure of realised performance in life settlement investing than internal rate of return, and he stresses transparency in portfolio reporting. - The reverse mortgage section says the U.S. agency-backed Home Equity Conversion Mortgage market continues to decline. - The latest U.S. government financial year recorded 24,182 HECM endorsements, the lowest annual total since 2003. - The article discusses possible regulatory reforms and the growing role of proprietary reverse mortgages.

Between the lines: - The issue shows how longevity-linked markets are increasingly tied to both demographic pressures and investor appetite for specialized, less correlated assets. - The HECM data suggests structural weakness in the agency-backed reverse mortgage market, which could speed calls for policy changes. - The dementia piece signals that medical progress may matter not only for public health, but also for pricing longevity risk.

What's next: - The publication says the market themes covered in the issue will continue to evolve as investors, insurers and regulators respond to demographic and capital-market shifts. - Further debate appears likely over life settlement standardisation, Irish structuring choices and reverse mortgage reform.

The bottom line: - The October 2026 issue frames longevity finance as a market in transition, with expansion opportunities in life settlements and fresh pressure on reverse mortgages.